T cell receptor recognizing melanoma peptide–HLA-A*02:01 complexes (TCR-Melanoma-HLA-A2)

The T cell receptor (TCR) recognizing melanoma peptide–HLA-A*02:01 complexes is a specialized immune receptor engineered or naturally selected to identify specific intracellular melanoma antigens presented on the cell surface. These antigens, such as MART-1, gp100, and MAGE family proteins, are processed into short peptides and displayed by the Human Leukocyte Antigen (HLA)-A*02:01 molecule (Nathan et al., NEJM 2021). The primary biological function of this TCR is to initiate an immune response by binding to these peptide-MHC (pMHC) complexes, which triggers T cell activation and the subsequent destruction of the melanoma cell via perforin and granzyme release (Morgan et al., Science 2006). In therapeutic applications, these TCRs are utilized in TCR-engineered T cell (TCR-T) therapies or as soluble bispecific engagers like Tebentafusp, which redirects polyclonal T cells to kill gp100-positive melanoma cells (Middleton et al., Clinical Cancer Research 2020). Because HLA-A*02:01 is one of the most common MHC alleles in Caucasian populations, it serves as a critical restriction element for broad clinical utility. However, safety challenges include 'on-target, off-tumor' toxicities, where the TCR recognizes the target antigen on healthy melanocytes in the skin, eye, or ear, potentially leading to vitiligo or uveitis (Blankenstein et al., Nature Reviews Cancer 2012). Monitoring for cytokine release syndrome is also essential during treatment with TCR-based therapies.

Other names

Melanoma-specific T cell receptorMART-1-specific TCRgp100-specific TCRMAGE-A3-specific TCRHLA-A*02:01 restricted T-cell receptorMelan-A TCR

T cell redirection and activation through specific binding to peptide-MHC complexes on tumor cells, leading to cytotoxic lymphocyte-mediated lysis of the target cell.